Therefore B-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

Psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost-effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
's I-Claim
mood I-Claim
and I-Claim
QOL I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
RT I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

Intrusive B-Claim
thoughts I-Claim
are I-Claim
associated I-Claim
with I-Claim
enduring I-Claim
elevations I-Claim
in I-Claim
behavioral I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
the I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
and I-Claim
may I-Claim
be I-Claim
a I-Claim
risk I-Claim
factor I-Claim
for I-Claim
poor I-Claim
outcomes I-Claim
. I-Claim

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Standard B-Claim
chemotherapy I-Claim
regimens I-Claim
are I-Claim
generally I-Claim
considered I-Claim
too I-Claim
toxic I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
. I-Claim

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
polycystic I-Claim
liver I-Claim
, I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
with I-Claim
lanreotide I-Claim
reduces I-Claim
liver I-Claim
volume I-Claim
. I-Claim

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

Lifestyle B-Claim
intervention I-Claim
research I-Claim
is I-Claim
feasible I-Claim
in I-Claim
a I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Lindberg I-Claim
flap I-Claim
. I-Claim

Patients B-Claim
receiving I-Claim
concomitant I-Claim
and I-Claim
maintenance I-Claim
temozolomide I-Claim
+ I-Claim
radiotherapy I-Claim
had I-Claim
significantly I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
ARSR I-Claim
between I-Claim
patients I-Claim
randomised I-Claim
to I-Claim
Calendula I-Claim
or I-Claim
Essex I-Claim
cream I-Claim
was I-Claim
found I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
recombinant I-Claim
human I-Claim
thyrotropin I-Claim
and I-Claim
low-dose I-Claim
( I-Claim
1.1 I-Claim
GBq I-Claim
) I-Claim
postoperative I-Claim
radioiodine I-Claim
ablation I-Claim
may I-Claim
be I-Claim
sufficient I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
low-risk I-Claim
thyroid I-Claim
cancer I-Claim
. I-Claim

It B-Claim
seems I-Claim
to I-Claim
be I-Claim
safe I-Claim
, I-Claim
and I-Claim
its I-Claim
long-term I-Claim
effectiveness I-Claim
is I-Claim
worthy I-Claim
of I-Claim
further I-Claim
investigation I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

The B-Claim
decrease I-Claim
in I-Claim
IEF I-Claim
and I-Claim
improvements I-Claim
in I-Claim
I-QoL I-Claim
scores I-Claim
were I-Claim
significantly I-Claim
greater I-Claim
in I-Claim
group I-Claim
A I-Claim
for I-Claim
the I-Claim
first I-Claim
16 I-Claim
wk I-Claim
. I-Claim

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti-TNF I-Claim
therapy I-Claim
. I-Claim

Epoetin B-Claim
beta I-Claim
30,000 I-Claim
IU I-Claim
once I-Claim
weekly I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
treatment I-Claim
of I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

More B-Claim
efficient I-Claim
treatment I-Claim
protocol I-Claim
is I-Claim
needed I-Claim
for I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
extensive-stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
EP I-Claim
regimen I-Claim
, I-Claim
the I-Claim
PCDE I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
SCLC I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
TOM I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
RR I-Claim
and I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
very I-Claim
close I-Claim
to I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
combination I-Claim
, I-Claim
and I-Claim
does I-Claim
not I-Claim
deserve I-Claim
further I-Claim
evaluation I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

Flavonoid-rich B-Claim
fruits I-Claim
and I-Claim
vegetables I-Claim
may I-Claim
provide I-Claim
additional I-Claim
protection I-Claim
against I-Claim
CINV I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single-agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Tamoxifen B-Claim
( I-Claim
TMX I-Claim
) I-Claim
is I-Claim
believed I-Claim
to I-Claim
inhibit I-Claim
HCC I-Claim
positive I-Claim
for I-Claim
estrogen I-Claim
receptor I-Claim
( I-Claim
ER I-Claim
) I-Claim
, I-Claim
but I-Claim
most I-Claim
HCCs I-Claim
are I-Claim
ER I-Claim
negative I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

Subjective B-Claim
benefit I-Claim
after I-Claim
intravenous I-Claim
pamidronate I-Claim
is I-Claim
confirmed I-Claim
in I-Claim
this I-Claim
placebo-controlled I-Claim
study I-Claim
. I-Claim

New B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

Compared B-Claim
with I-Claim
multiple-fraction I-Claim
radiotherapy I-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
provides I-Claim
equal I-Claim
palliation I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
has I-Claim
lower I-Claim
medical I-Claim
and I-Claim
societal I-Claim
costs I-Claim
, I-Claim
at I-Claim
least I-Claim
in I-Claim
The I-Claim
Netherlands I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
was I-Claim
associated I-Claim
with I-Claim
greater I-Claim
and I-Claim
longer-lasting I-Claim
improvement I-Claim
in I-Claim
several I-Claim
HQL I-Claim
domains I-Claim
and I-Claim
symptoms I-Claim
than I-Claim
treatment I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

Protein B-Premise
intake I-Premise
also I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73.5 I-Premise
IU/L I-Premise
and I-Premise
86.3 I-Premise
IU/L I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non-responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept-treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59.4 I-Premise
% I-Premise
and I-Premise
56.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23.5 I-Premise
% I-Premise
and I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11.5 I-Premise
% I-Premise
and I-Premise
16.1 I-Premise
% I-Premise
";" I-Premise
HAQ-DI I-Premise
responses I-Premise
were I-Premise
54.4 I-Premise
% I-Premise
and I-Premise
47.9 I-Premise
% I-Premise
. I-Premise

Patients B-Premise
who I-Premise
had I-Premise
no I-Premise
preference I-Premise
had I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
AET I-Premise
compared I-Premise
with I-Premise
RET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
23 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.9-41 I-Premise
";" I-Premise
P= I-Premise
.014 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
duration I-Premise
for I-Premise
the I-Premise
stage I-Premise
IIIB I-Premise
subgroup I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
patients I-Premise
versus I-Premise
13.1 I-Premise
months I-Premise
for I-Premise
all I-Premise
paclitaxel I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.152 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
more I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
performance I-Premise
status I-Premise
( I-Premise
P=0.065 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
and I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
( I-Premise
0.06 I-Premise
kg I-Premise
, I-Premise
gain I-Premise
of I-Premise
0.08 I-Premise
kg I-Premise
, I-Premise
and I-Premise
2.27 I-Premise
kg I-Premise
for I-Premise
DC I-Premise
, I-Premise
DCb I-Premise
, I-Premise
and I-Premise
VC I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
both I-Premise
DC I-Premise
versus I-Premise
VC I-Premise
and I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P=.05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
the I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
of I-Premise
rheumatoid I-Premise
arthritis I-Premise
, I-Premise
physical I-Premise
function I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
observed I-Premise
after I-Premise
6 I-Premise
months I-Premise
, I-Premise
were I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
in I-Premise
this I-Premise
population I-Premise
with I-Premise
difficult-to-treat I-Premise
disease I-Premise
. I-Premise

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
QoL I-Premise
investigation I-Premise
, I-Premise
the I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
dropped I-Premise
for I-Premise
all I-Premise
patients I-Premise
at I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
was I-Premise
4.7 I-Premise
vs. I-Premise
5.8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

Severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib-treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow-up I-Premise
. I-Premise

Global B-Premise
QOL I-Premise
, I-Premise
emotional/role I-Premise
functioning I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
pain I-Premise
, I-Premise
swallowing I-Premise
, I-Premise
speech I-Premise
, I-Premise
social I-Premise
contact/eating I-Premise
, I-Premise
insomnia I-Premise
showed I-Premise
rapid I-Premise
recovery I-Premise
( I-Premise
< I-Premise
6months I-Premise
) I-Premise
while I-Premise
physical/cognitive I-Premise
functioning I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
sticky I-Premise
saliva I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
senses I-Premise
showed I-Premise
delayed I-Premise
recovery I-Premise
( I-Premise
> I-Premise
6months I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
and I-Premise
placebo I-Premise
was I-Premise
2.7 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
1.36 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.51 I-Premise
) I-Premise
. I-Premise

A B-Premise
similar I-Premise
change I-Premise
was I-Premise
seen I-Premise
for I-Premise
mean I-Premise
anxiety I-Premise
scores I-Premise
: I-Premise
intervention I-Premise
11.1 I-Premise
to I-Premise
8.2 I-Premise
, I-Premise
control I-Premise
9.6 I-Premise
to I-Premise
9.3 I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
17.8 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Severe B-Premise
HSRs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise

18 B-Premise
months I-Premise
post-surgery I-Premise
approximately I-Premise
twice I-Premise
as I-Premise
many I-Premise
patients I-Premise
in I-Premise
the I-Premise
standard I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
SNB I-Premise
group I-Premise
reported I-Premise
substantial I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
14 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
or I-Premise
numbness I-Premise
( I-Premise
19 I-Premise
% I-Premise
versus I-Premise
8.7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

While B-Premise
myelosuppression I-Premise
was I-Premise
significantly I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
combination I-Premise
, I-Premise
sequelae I-Premise
such I-Premise
as I-Premise
febrile I-Premise
neutropenia I-Premise
or I-Premise
infections I-Premise
were I-Premise
uncommon I-Premise
. I-Premise

Although B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
FLOT I-Premise
, I-Premise
no B-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
addition I-Premise
of I-Premise
docetaxel I-Premise
on I-Premise
QOL I-Premise
parameters I-Premise
could I-Premise
be I-Premise
demonstrated I-Premise
. I-Premise

PFS B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
than I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.68 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
risk I-Premise
of I-Premise
progression I-Premise
. I-Premise

No B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22.8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
E I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0388 I-Premise
) I-Premise
. I-Premise

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
ARSR I-Premise
( I-Premise
RTOG/EORTC I-Premise
grade I-Premise
≤2 I-Premise
) I-Premise
at I-Premise
the I-Premise
follow-up I-Premise
visit I-Premise
was I-Premise
23 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
45 I-Premise
) I-Premise
in I-Premise
the I-Premise
Calendula I-Premise
group I-Premise
and I-Premise
19 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
in I-Premise
the I-Premise
Essex I-Premise
group I-Premise
. I-Premise

QOL B-Premise
was I-Premise
preserved I-Premise
longer I-Premise
for I-Premise
patients I-Premise
on I-Premise
DCF I-Premise
than I-Premise
those I-Premise
on I-Premise
CF I-Premise
for I-Premise
all I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
analyses I-Premise
, I-Premise
demonstrating I-Premise
the I-Premise
statistical I-Premise
superiority I-Premise
of I-Premise
DCF I-Premise
compared I-Premise
with I-Premise
CF I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

Survival B-Premise
without I-Premise
performance-status I-Premise
deterioration I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain-free I-Premise
survival I-Premise
( I-Premise
p=0.003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
QOL I-Premise
between I-Premise
LRP I-Premise
and I-Premise
ORP I-Premise
. I-Premise

Asymptomatic B-Premise
Corrected I-Premise
QT I-Premise
interval I-Premise
( I-Premise
QTC I-Premise
) I-Premise
prolongation I-Premise
was I-Premise
observed I-Premise
in I-Premise
eight I-Premise
vandetanib I-Premise
patients I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

The B-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
18 I-Premise
incidences I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
( I-Premise
eg I-Premise
, I-Premise
nausea I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
dizziness I-Premise
, I-Premise
anxiety I-Premise
) I-Premise
, I-Premise
whereas I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
experienced I-Premise
no I-Premise
negative I-Premise
adverse I-Premise
effects I-Premise
. I-Premise

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Forty-six B-Premise
patients I-Premise
( I-Premise
88 I-Premise
% I-Premise
) I-Premise
were I-Premise
in I-Premise
disease I-Premise
remission I-Premise
12 I-Premise
months I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
relationships I-Premise
between I-Premise
biomarker I-Premise
expression I-Premise
and I-Premise
outcomes I-Premise
were I-Premise
observed I-Premise
. I-Premise

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
wild-type I-Premise
status I-Premise
who I-Premise
received I-Premise
cetuximab I-Premise
experienced I-Premise
improved I-Premise
GHS I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
who I-Premise
received I-Premise
BSC I-Premise
alone I-Premise
deteriorated I-Premise
( I-Premise
3.2 I-Premise
v I-Premise
-7.7 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
groups I-Premise
was I-Premise
similar I-Premise
. I-Premise

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Additional B-Premise
analyses I-Premise
yielded I-Premise
quadratic I-Premise
interactions I-Premise
for I-Premise
exercise I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.022 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
, I-Premise
and I-Premise
for I-Premise
stress I-Premise
management I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SM I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SM I-Premise
and I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Similar B-Premise
trends I-Premise
in I-Premise
survival I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
were I-Premise
seen I-Premise
for I-Premise
men I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
65 I-Premise
years I-Premise
of I-Premise
age I-Premise
, I-Premise
for I-Premise
those I-Premise
with I-Premise
and I-Premise
without I-Premise
pain I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
for I-Premise
those I-Premise
with I-Premise
baseline I-Premise
PSA I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
the I-Premise
median I-Premise
value I-Premise
of I-Premise
115 I-Premise
ng/mL I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
single- I-Premise
and I-Premise
multiple-fraction I-Premise
radiotherapy I-Premise
schedules I-Premise
, I-Premise
no I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
43.0 I-Premise
versus I-Premise
40.4 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.20 I-Premise
) I-Premise
or I-Premise
quality-adjusted I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
17.7 I-Premise
versus I-Premise
16.0 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.21 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise

Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
were I-Premise
-1.0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-1.5 I-Premise
to I-Premise
-0.5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0.2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.2 I-Premise
to I-Premise
+0.6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
and I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
were I-Premise
6.2 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.20-1.43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

The O
trial O
was O
prematurely O
closed O
during O
recruitment O
, O
after O
a O
median O
follow-up O
of O
11.9 O
months O
( O
interquartile O
range O
7.1-19.6 O
, O
total O
6498 O
women O
years O
) O
in O
those O
enrolled O
, O
after O
the O
publication O
of O
early O
results O
from O
the O
women O
's O
health O
initiative O
study O
. O

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health-related O
quality-of-life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

The O
median O
follow-up O
was O
22.6 O
months O
. O

Data O
on O
survival O
time O
and O
medical O
care O
resource O
use O
were O
prospectively O
collected O
in O
the O
trial O
. O

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single-agent O
gemcitabine O
as O
first-line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
2 O
tertiary O
referral O
centers O
. O

This O
trial O
was O
conducted O
to O
determine O
whether O
high-dose O
fluorouracil O
( O
FU O
) O
given O
as O
a O
weekly O
24-hour O
infusion O
is O
more O
active O
than O
bolus O
FU O
+ O
leucovorin O
( O
LV O
) O
, O
and O
whether O
high-dose O
infusional O
FU O
can O
be O
modulated O
by O
LV O
. O

We O
assessed O
whether O
such O
patients O
could O
be O
helped O
if O
a O
practitioner O
followed O
an O
investigative O
and O
management O
algorithm O
, O
and O
whether O
outcomes O
differed O
by O
whether O
a O
nurse O
or O
a O
gastroenterologist O
led O
this O
algorithm-based O
care O
. O

Eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
IV O
or O
IIIB O
NSCLC O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0-2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self-care O
but O
unable O
to O
work O
) O
. O

To O
compare O
the O
effects O
of O
cannabis O
extract O
( O
CE O
) O
, O
delta-9-tetrahydrocannabinol O
( O
THC O
) O
, O
and O
placebo O
( O
PL O
) O
on O
appetite O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer-related O
anorexia-cachexia O
syndrome O
( O
CACS O
) O
. O

The O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
RR O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
RR O
with O
the O
standard O
treatment O
if O
the O
TRUE O
difference O
is O
15 O
% O
or O
more O
. O

Breast O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
is O
a O
technique O
that O
ensures O
a O
more O
homogeneous O
dose O
distribution O
. O

QoL O
was O
the O
first O
endpoint O
and O
the O
statistical O
power O
was O
inadequate O
to O
assess O
other O
parameters O
. O

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

To O
compare O
the O
outcome O
of O
treatment O
of O
mediastinoscopy-verified O
N2 O
non-small-cell O
lung O
cancer O
treated O
with O
induction O
chemotherapy O
followed O
by O
either O
surgery O
or O
radiotherapy O
( O
RT O
) O
, O
with O
both O
options O
followed O
by O
consolidation O
chemotherapy O
. O

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O

Patients O
with O
hormone-refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double-blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
N O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
";" O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
or O
placebo O
( O
N O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O

No O
androgen O
deprivation O
was O
allowed O
. O

Symptom O
and O
quality O
of O
life O
( O
QOL O
) O
status O
was O
determined O
with O
use O
of O
questionnaires O
. O

( O
7,000 O
mg/m O
( O
2 O
) O
day O
1 O
of O
a O
28-day O
cycle O
) O
or O
p.o O
. O

Thirty O
two O
percent O
of O
women O
randomly O
assigned O
had O
estrogen O
and O
progesterone O
receptor-negative O
breast O
cancer O
, O
42 O
% O
had O
visceral O
metastases O
, O
and O
58 O
% O
had O
bone O
metastases O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

Between O
April O
1990 O
and O
April O
1994 O
, O
70 O
eligible O
patients O
participated O
in O
a O
phase O
III O
trial O
comparing O
a O
regimen O
containing O
sequential O
chemotherapy O
and O
radiation O
therapy O
versus O
sequential O
chemotherapy O
plus O
surgery O
. O

Using O
a O
single-blinded O
, O
3-armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O

Health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
of O
depression O
, O
and O
adverse O
events O
( O
AEs O
) O
were O
compared O
between O
Japanese O
postmenopausal O
patients O
with O
hormone-sensitive O
breast O
cancer O
( O
BC O
) O
who O
received O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
in O
an O
open-labeled O
, O
randomized O
, O
multicenter O
trial O
designated O
as O
the O
National O
Surgical O
Adjuvant O
Study O
of O
Breast O
Cancer O
( O
N-SAS O
BC O
) O
4 O
substudy O
of O
the O
Tamoxifen O
Exemestane O
Adjuvant O
Multinational O
( O
TEAM O
) O
trial O
. O

Each O
call O
was O
standardized O
, O
comprising O
the O
assessment O
of O
unmet O
need O
and O
the O
provision O
of O
information O
and O
emotional O
support O
. O

Data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
IDT O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O

Patients O
with O
breast O
cancer O
reporting O
treatment-induced O
menopausal O
symptoms O
( O
N=422 O
) O
were O
randomly O
assigned O
to O
CBT O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
CBT/PE O
( O
n=106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n=103 O
) O
. O

Forty-six O
patients O
( O
mean O
age O
, O
66 O
yrs O
";" O
57 O
% O
women O
) O
contributed O
data O
to O
the O
trial O
. O

Follow-up O
assessment O
for O
our O
primary O
end O
point O
was O
96 O
% O
( O
117 O
of O
122 O
) O
at O
postintervention O
and O
90 O
% O
( O
110 O
of O
122 O
) O
at O
6-month O
follow-up O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

Small O
improvements O
in O
pain O
and O
mood O
are O
observed O
despite O
progressive O
functional O
decline O
. O

Two O
primary O
end O
points O
were O
examined O
: O
energy/fatigue O
and O
cancer-specific O
distress O
. O

Survival O
curves O
were O
drawn O
using O
the O
Kaplan-Meier O
method O
and O
analyzed O
by O
the O
Mantel-Haenszel O
test O
. O

We O
compared O
the O
combination O
of O
docetaxel-carboplatin O
with O
the O
combination O
of O
paclitaxel-carboplatin O
as O
first-line O
chemotherapy O
for O
stage O
Ic-IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

Patient O
data O
regarding O
transfusions O
, O
epoetin-alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow-up O
for O
12-36 O
months O
post-study O
. O

The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
";" O
MIC O
, O
61 O
% O
) O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

We O
investigated O
the O
role O
of O
DC/CIK O
( O
dendritic O
cell/cytokine-induced O
killer O
cells O
) O
immunobiological O
cancer O
therapy O
in O
maintenance O
therapy O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

Forty-one O
participants O
were O
enrolled O
and O
36 O
completed O
the O
trial O
. O

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

If O
the O
intervention O
period O
was O
prolonged O
, O
we O
might O
get O
different O
conclusion O
. O

Patients O
and O
investigators O
were O
masked O
to O
CA125 O
results O
, O
which O
were O
monitored O
by O
coordinating O
centres O
. O

At O
baseline O
, O
15 O
% O
of O
patients O
were O
sexually O
active O
";" O
this O
increased O
significantly O
to O
39 O
% O
during O
the O
first O
year O
( O
P O
< O
.001 O
) O
. O

An O
interim O
analysis O
showed O
futility O
, O
and O
the O
results O
are O
presented O
with O
an O
adjusted O
one-sided O
alpha O
level O
of O
0.0429 O
. O

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

Both B-Premise
groups I-Premise
showed I-Premise
an I-Premise
increase I-Premise
in I-Premise
symptom I-Premise
and I-Premise
interference I-Premise
scores I-Premise
, I-Premise
although O
patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
both I-Premise
scores I-Premise
during I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
. I-Premise

The B-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
no I-Premise
change I-Premise
in I-Premise
OPS-DNA I-Premise
concentration I-Premise
, I-Premise
although O
the B-Premise
placebo I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
DNA I-Premise
concentration I-Premise
during I-Premise
the I-Premise
drug I-Premise
trial I-Premise
( I-Premise
P=.045 I-Premise
) I-Premise
. I-Premise

Experimental B-Claim
and I-Claim
early I-Claim
clinical I-Claim
investigations I-Claim
have I-Claim
demonstrated I-Claim
encouraging I-Claim
results I-Claim
for I-Claim
estramustine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
malignant I-Claim
glioma I-Claim
. O

We O
conclude O
that O
three B-Claim
cycles I-Claim
of I-Claim
BEP I-Claim
, I-Claim
with I-Claim
etoposide I-Claim
at I-Claim
500 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
is I-Claim
sufficient I-Claim
therapy I-Claim
in I-Claim
good-prognosis I-Claim
germ I-Claim
cell I-Claim
cancer I-Claim
and O
that O
the B-Claim
administration I-Claim
of I-Claim
the I-Claim
chemotherapy I-Claim
in I-Claim
3 I-Claim
days I-Claim
has I-Claim
no I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
the I-Claim
effectiveness I-Claim
of I-Claim
the I-Claim
BEP I-Claim
regimen I-Claim
. I-Claim

For B-Claim
those I-Claim
patients I-Claim
who I-Claim
recur I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
after I-Claim
initial I-Claim
therapy I-Claim
, I-Claim
paclitaxel I-Claim
platinum I-Claim
has I-Claim
shown I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
platinum I-Claim
without I-Claim
paclitaxel I-Claim
";" I-Claim
however B-Premise
, I-Premise
many I-Premise
patients I-Premise
develop I-Premise
clinically I-Premise
relevant I-Premise
neurotoxicity I-Premise
, I-Premise
frequently I-Premise
resulting I-Premise
in I-Premise
treatment I-Premise
discontinuation I-Premise
. O

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

Anti-aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

Consistent O
with O
the O
2-year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient-reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
tamoxifen I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18.5 I-Premise
% I-Premise
vs. I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34.0 I-Premise
% I-Premise
vs. I-Premise
26.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17.3 I-Premise
% I-Premise
vs. I-Premise
8.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
GJJ I-Claim
, O
although B-Claim
GJJ I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim

Also O
, O
the B-Premise
Kaplan-Meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log-rank I-Premise
test I-Premise
( I-Premise
p=0.286 I-Premise
) I-Premise
. I-Premise

CAF B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise

Recruitment O
was O
stopped O
after O
the B-Premise
first I-Premise
planned I-Premise
interim I-Premise
analysis I-Premise
in I-Premise
February I-Premise
2006 I-Premise
( I-Premise
n=150 I-Premise
) I-Premise
showed I-Premise
that I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
sertraline I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.60 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.04-2.45 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.04 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.62 I-Premise
[ I-Premise
1.06-2.41 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

The B-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
proved I-Claim
to I-Claim
be I-Claim
feasible I-Claim
: I-Claim
75.0 B-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
read I-Premise
the I-Premise
entire I-Premise
pain I-Premise
brochure I-Premise
, I-Premise
55.7 I-Premise
% I-Premise
had I-Premise
listened I-Premise
to I-Premise
the I-Premise
audio I-Premise
cassette I-Premise
, I-Premise
and I-Premise
85.6 I-Premise
% I-Premise
of I-Premise
pain I-Premise
scores I-Premise
were I-Premise
completed I-Premise
in I-Premise
the I-Premise
pain I-Premise
diary I-Premise
. I-Premise

In O
particular O
, O
physical B-Premise
functioning I-Premise
remains I-Premise
deteriorated I-Premise
1 I-Premise
year I-Premise
after I-Premise
inclusion I-Premise
for I-Premise
HDC I-Premise
patients I-Premise
comparatively I-Premise
to I-Premise
conventional I-Premise
chemotherapy I-Premise
patients I-Premise
( I-Premise
85.99 I-Premise
vs. I-Premise
76.65 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
) I-Premise
, O
and B-Premise
the I-Premise
pain I-Premise
score I-Premise
was I-Premise
still I-Premise
higher I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
at I-Premise
that I-Premise
time I-Premise
( I-Premise
28.32 I-Premise
vs. I-Premise
15.97 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

While O
the B-Claim
short-term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
TPV I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
LUTS I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin-releasing I-Claim
hormone I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and/or I-Claim
the I-Claim
prostate I-Claim
. I-Claim

Furthermore O
, O
no B-Premise
differences I-Premise
between I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
and I-Premise
their I-Premise
corresponding I-Premise
control I-Premise
groups I-Premise
were I-Premise
found I-Premise
in I-Premise
role I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
feelings I-Premise
of I-Premise
control I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
p-values I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Specifically O
, O
AET B-Premise
improved I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
in I-Premise
patients I-Premise
with I-Premise
lymphoma I-Premise
who I-Premise
had I-Premise
indolent I-Premise
non-Hodgkin I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
were I-Premise
receiving I-Premise
chemotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
were I-Premise
< I-Premise
2 I-Premise
years I-Premise
post-diagnosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
were I-Premise
obese I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
, I-Premise
and I-Premise
were I-Premise
poor I-Premise
sleepers I-Premise
at I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.007 I-Premise
) I-Premise
. I-Premise

Both B-Claim
drugs I-Claim
could I-Claim
improve I-Claim
the I-Claim
QoL I-Claim
, I-Claim
but O
Gefitinib B-Claim
showed I-Claim
better I-Claim
overall I-Claim
results I-Claim
than I-Claim
Pemetrexed I-Claim
. I-Claim

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long-term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

Hence O
, O
equivalence B-Claim
is I-Claim
claimed I-Claim
in I-Claim
this I-Claim
comparison I-Claim
also I-Claim
. I-Claim

The B-Claim
timing I-Claim
of I-Claim
RT I-Claim
has I-Claim
minimal I-Claim
impact I-Claim
on I-Claim
the I-Claim
function I-Claim
of I-Claim
STS I-Claim
patients I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
surgery I-Claim
. O

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

After B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
HQL I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
( I-Premise
.004 I-Premise
< I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

In O
a O
retrospective O
analysis O
, O
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
pamidronate I-Premise
90 I-Premise
mg I-Premise
group I-Premise
developed I-Premise
osteonecrosis I-Premise
of I-Premise
the I-Premise
jaw I-Premise
compared I-Premise
with I-Premise
two I-Premise
patients I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
. I-Premise

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18-108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

DC-treated B-Premise
patients I-Premise
experienced I-Premise
improved I-Premise
pain I-Premise
relief I-Premise
compared I-Premise
with I-Premise
VC I-Premise
( I-Premise
P=0.033 I-Premise
) I-Premise
, I-Premise
whereas O
pain B-Premise
relief I-Premise
with I-Premise
DCb I-Premise
and I-Premise
VC I-Premise
was I-Premise
similar I-Premise
. I-Premise

Triglycerides B-Premise
and I-Premise
high-density I-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and O
low-density B-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
1-year I-Premise
study I-Premise
period I-Premise
. I-Premise

Chemotherapy B-Claim
seems I-Claim
to I-Claim
improve I-Claim
symptoms I-Claim
control I-Claim
, I-Claim
even O
if O
randomised O
studies O
with O
quality O
of O
life O
as O
first O
endpoint O
are O
lacking O
and O
often O
chemotherapy O
toxicity O
compromises O
the O
frail O
cost/benefit O
ratio O
. O

Also O
, O
a B-Premise
significant I-Premise
reduction I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
in I-Premise
incidence I-Premise
of I-Premise
severe I-Premise
OM I-Premise
, I-Premise
need I-Premise
for I-Premise
opioid I-Premise
analgesics I-Premise
, I-Premise
and I-Premise
total I-Premise
parenteral I-Premise
nutrition I-Premise
was I-Premise
observed I-Premise
. I-Premise

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18.9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

Myelosuppression B-Premise
, I-Premise
renal I-Premise
insufficiency I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but O
skin B-Premise
toxicities I-Premise
and I-Premise
liver I-Premise
dysfunction I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
. I-Premise

Gastrointestinal B-Premise
toxicity I-Premise
of I-Premise
pamidronate I-Premise
caused I-Premise
a I-Premise
23 I-Premise
% I-Premise
drop-out I-Premise
rate I-Premise
, I-Premise
but B-Claim
other I-Claim
cancer-associated I-Claim
factors I-Claim
seemed I-Claim
to I-Claim
contribute I-Claim
to I-Claim
this I-Claim
toxicity I-Claim
. I-Claim

Alternating O
, O
schedule-specific B-Claim
biochemical I-Claim
modulation I-Claim
of I-Claim
FU I-Claim
is I-Claim
more I-Claim
active I-Claim
than I-Claim
MTX I-Claim
-- I-Claim
> I-Claim
5-FU I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin-alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0.126 I-Premise
] I-Premise
) I-Premise
. I-Premise

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

Patients B-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
do I-Claim
not I-Claim
have I-Claim
curative I-Claim
treatment I-Claim
options I-Claim
";" I-Claim
therefore O
, O
treatments O
should O
prolong O
survival O
and O
improve O
quality O
of O
life O
( O
QoL O
) O
. O

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

Whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
RDI I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
=-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
CI I-Premise
-1.0 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.9 I-Premise
to I-Premise
0.1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65-175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim

Experimental B-Claim
surgery I-Claim
on I-Claim
pigs I-Claim
has I-Claim
suggested I-Claim
that I-Claim
a I-Claim
coloplasty I-Claim
pouch I-Claim
( I-Claim
CP I-Claim
) I-Claim
may I-Claim
be I-Claim
a I-Claim
useful I-Claim
alternative I-Claim
. O

However O
, O
when B-Premise
compared I-Premise
with I-Premise
sham I-Premise
acupuncture I-Premise
, I-Premise
the I-Premise
reduction I-Premise
by I-Premise
the I-Premise
acupuncture I-Premise
regimen I-Premise
as I-Premise
provided I-Premise
in I-Premise
the I-Premise
current I-Premise
study I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

In O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
Group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre-exercise I-Premise
period I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

